SCHEMBL1581950

SCHEMBL1581950

CCOC(=O)C=CC1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.47
L3MBTL1 Q9Y468 4/20 0.41
LMNA P02545 1/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
THRB P10828 1/20 0.39
ATM Q13315 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9744701 1.00 HCAR2 (0.47) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL9744705 1.00 HCAR2 (0.47) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL1581948 1.00 HCAR2 (0.47) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL14363086 1.00 HCAR2 (0.47) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL425749 0.98 HCAR2 (0.48) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL425748 0.98 HCAR2 (0.48) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL1126533 0.94 HCAR2 (0.48) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL1126534 0.94 HCAR2 (0.48) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL587678 0.91 HCAR2 (0.43) HCAR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL7512241 0.90 HCAR2 (0.52) HCAR2L3MBTL1LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024055226-A1 AROMATIC AND HETEROAROMATIC COMPOUNDS PREPARING FROM EXO-CYCLIC π-SYSTEMS. SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2024-03-21 WO claimed
US-9771358-B2 Dihydropyrimidine compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-09-26 US disclosed
US-20160347746-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-12-01 US disclosed
US-8227516-B2 Compounds as histone deacetylase inhibitors 4SC DISCOVERY GMBH (DE) 2012-07-24 US disclosed
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20090088478-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS 4SC DISCOVERY GMBH (DE) 2009-04-02 US disclosed
US-20090012320-A1 Method for the Production of Olefins from Carbonyl Compounds STUDIENGESELLSCHAFT KOHLE MBH (DE) 2009-01-08 US disclosed
US-20070276153-A1 Diastereoselective Method of Preparing Olefins by Means of the Horner-Wadsworth-Emmons Reaction Using a Particular Phosphonate Which Improves Diastereoselectivity at all Temperatures Including at Ambient Temperature RHODIA UK LIMITED (GB) 2007-11-29 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed
WO-2004009536-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2004-01-29 WO disclosed
US-5621133-A PREPARING A 1-(3,4-DIALKOXYPHENYL),3-HYDROXYALKANE(C6-C12) BY EPOXIDIZING A HALO DERIVATIVE WITH A BASE FOLLOWED BY DECYCLICIZING WITH AN ORGANOMETALLIC COMPOUND IN A SOLVENT; NAPHTHYLENES, ISOCHROMENES AND ISOTHIOCHROMENES DENINNO MICHAEL P (US) 1997-04-15 US disclosed
US-5591884-A PROTECTED HYDROXYALKYLCATECHOL INTERMEDIATES ABBOTT LABORATORIES (US) 1997-01-07 US disclosed
WO-1996038435-A1 DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1996-12-05 WO disclosed
EP-0474767-B1 DOPAMINE AGONISTS ABBOTT LAB (US) 1996-02-21 EP disclosed
EP-0474767-A4 DOPAMINE AGONISTS 1992-07-08 EP disclosed
EP-0474767-A1 DOPAMINE AGONISTS. ABBOTT LAB (US) 1992-03-18 EP disclosed
WO-1990015056-A1 DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1990-12-13 WO disclosed
US-4963568-A TREATMENT OF PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS ABBOTT LABORATORIES (US) 1990-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088478-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC5 HCAR2 1072/4885L3MBTL1 1003/4885LMNA 1717/4885
US-20160347746-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS DPYD, SLC10A1, HPRT1 HCAR2 1997/4885L3MBTL1 4328/4885LMNA 1975/4885
US-20090012320-A1 Method for the Production of Olefins from Carbonyl Compounds COASY, FASN, PTGES HCAR2 416/4885L3MBTL1 3168/4885LMNA 2047/4885
US-20070276153-A1 Diastereoselective Method of Preparing Olefins by Means of the Horner-Wadsworth-Emmons Reaction Using a Particular Phosphonate Which Improves Diastereoselectivity at all Temperatures Including at Ambient Temperature GGPS1, OXER1, ALOX12 HCAR2 3748/4885L3MBTL1 4146/4885LMNA 3517/4885
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 HCAR2 1938/4885L3MBTL1 4659/4885LMNA 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.